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Abstract Background: Chronic obstructive pulmonary disease (COPD) is a debilitating disease and places a large fi-
nancialburden onhealth-care systems and society.Weprospectivelyevaluated the cost-effectiveness of fluticasonepro-
pionate (FP) treatment in patients withmoderate-to-severe COPD, whowere symptomatic on regular bronchodilator
therapy.Methods: An economic analysiswas performed in a 6-month, randomized, double-blind clinical trial comparing
FP1000 mg/day with placebo in 281patients aged 45^79 years with symptomatic moderate-to-severe COPD.Data on
clinicalefficacy, health-careresourceuse andproductivityloss associatedwiththemanagementof COPDwereprospec-
tivelycollected.Themainoutcomemeasuresweretheincrementalcost^effectivenessof achievingaZ10% improvement
in FEV1andofremainingexacerbation-freethroughoutthe study.The economicevaluationwas costed fromtheperspec-
tive of the NHS (direct costs) and of society (direct and indirect costs). Results: FP was significantlymore effective than
placebo in terms of the proportions of patients demonstrating aZ10% improvement in FEV1 (32 vs.19%; P¼0.02) and
remaining free ofmoderate/severe exacerbations (75 vs.63%; P¼0.02).The difference betweenthe groups in total costs
was not significantly different. Incremental cost^effectiveness analyses showed thatthe additional clinical benefits of FP
relativetoplacebo, intermsof aZ10% improvementin FEV1or anincreasednumberofpatients free ofmoderate/severe
exacerbations, were achievedatminimaladditionalcosts fromanNHSperspective (additional d0.25 perday forboth) or
at a net saving from a societal perspective. Sensitivity analysis showed that these results were robust to changes in the
underlying assumptions.Conclusions:Treatment with FP was associatedwith statistically significantclinical benefits in pa-
tients withmoderate-to-severe COPD currently symptomatic on regular bronchodilator therapy. As the differences in
direct and total costs compared with placebo were small and non-significant, this treatment can be considered cost-
effective inthis patient population.r2002 Publishedby Elsevier Science Ltd.
Available online athttp://www.sciencedirect.com
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Chronic obstructive pulmonary disease (COPD) repre-
sents an increasingly important global health-care chal-
lenge. Currently, an estimated 44 million people
worldwide su¡er from symptomatic COPD (1).The Glo-
bal Burden of Disease study ranked COPD as the sixth
leading cause of mortality and the 12th leading cause of
morbidity (2). By 2020, COPD will rise, to become the
third leading cause of mortality and the ¢fth leading
cause of morbidity worldwide (3). In the U.K. alone,Accepted in revised form 28 August 2002.
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(4), and 26 000 deaths are attributed to the disease an-
nually (5).
Airway in£ammation plays a key role in the pathogen-
esis of COPD (6), which provides a rationale for the use
of inhaled corticosteroids in this condition (7^9).
Although these agents have no e¡ect on the rate of de-
cline in lung function (10^12), recent large, long-term,
placebo-controlled studies have shown that £uticasone
propionate (FP) canbene¢t lung function, symptoms, ex-
acerbations andhealth status in patients withmoderate-
to-severe COPD (12,13).
While there is some evidence of clinical bene¢t from
inhaled corticosteroids in COPD, the cost^e¡ectiveness
of these drugs is unknown and needs to be addressed,
particularly given the chronic nature of the disease and
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managing COPD exacerbations are substantial; in 1995,
the cost of COPD to the U.K. NHS was estimated at
almost d500 million, of which 36% was spent on emer-
gency hospital admissions (15).The total cost is consider-
ably higher when one considers the COPD-related
productivity loss, which in the U.K. is estimated to be
d1.5 billion.
The aim of this analysis was to evaluate the cost-e¡ec-
tiveness of adding FP to regular bronchodilator therapy
in symptomatic patients with moderate-to-severe
COPD, in a double-blind, randomized, placebo-con-
trolled study over 6 months.
METHODS
Study design
The economic analysis was based on a 6 month, interna-
tional, multicentre, randomized, double-blind, parallel-
group, placebo-controlled trial assessing the e¡ect of in-
haled FP in the treatment of symptomatic patients with
moderate-to-severe COPD. Investigating physicians
also (13) made sure that the patients’ histories were in
keeping with the description of COPD in the European
Respiratory Society Consensus Statement (16), and that
thosewith a history of asthmawere excluded.The inclu-
sion criteria were as follows: current/ex-smokers; his-
tory of Z1 COPD exacerbation each year in the
previous 3 years requiring a doctor or hospital visit; high
expectation of a COPD exacerbation during the study;
regular productive cough; predicted FEV1 of 35^90%;
FEV1 to forced vital capacity (FVC) ratio of 70% or less;
and FEV1reversibility ofo15% frombaseline after inhala-
tion of salbutamol 400 or 800mg.Patientswere excluded
if theyhad an abnormal chestradiograph or hadreceived
oral or depot corticosteroids, inhaled corticosteroids
(Z500mg/day) or antibiotic therapy or had been ad-
mitted to hospital in the previous 4 weeks, or were cur-
rently taking FP.
Patients who met the inclusion criteria entered
into a 2-week run-in period, during which inhaled
corticosteroid therapy was stopped. Patients were
required to be symptomatic on at least 4 of the 14 days
during the run-in. Eligible patients were randomized
to two pu¡s of FP 250mg twice daily (i.e. 1000mg daily)
or two pu¡s of placebo twice daily via metered dose
inhalers with or without a spacer, depending on
assessment of inhaler technique. Patients could take
rescue short-acting b2-agonists as required. Other
COPD medications, such as anticholinergics and
methylxanthines, could be continued throughout the
study without dose changes. Patients visited the clinics
at weeks 4, 8,16 and 24.Measures of e¡ectiveness
Improvement in FEV1
For the purpose of this analysis, a dichotomous success/
failure approachwas taken.The criterion for successwas
aZ10% improvement in FEV1frombaseline by the end of
treatment, as this was considered to represent a clini-
cally relevant improvement. This level of improvement
in FEV1is also theminimumchange that canbeperceived
by asthma patients (17). The proportion of patients
achieving this improvement was calculated for each
treatment group.
Exacerbation-free patient
An exacerbation was de¢ned as a worsening of COPD
symptoms requiring a change to normal treatment, in-
cluding antibiotics, short courses of oral corticosteroids,
and other bronchodilators. Exacerbations were either
mild (managed by the patient), moderate (requiring
treatment by a physician) or severe (resulting in admis-
sion to hospital). The proportion of patients remaining
free of exacerbations over the 6 months of the study
was the outcomemeasure used in the analysis.The pro-
portion of patients free of moderate/severe exacerba-
tions, which are considered to be of greater clinical
importance thanmild exacerbationsmanagedby the pa-
tient, was also evaluated.
Resource utilization
Data on health-care resource utilization associatedwith
COPD exacerbations were prospectively collected
throughout the study and recorded by the investigators
on a separate form.Data collected includedutilization of
inpatient, outpatient and primary health-care services.
Time lost from usual activities and paid employment be-
cause of exacerbations was also recorded, together with
COPD-related concurrentmedications and rescuemed-
ication use.
Economic analysis
The prospective economic analysis was conducted from
a U.K. NHS perspective with direct (health-care) re-
sources costedusingpublished information at1998prices
(18). In addition, aU.K. societal perspectivewas taken, by
recording indirect costs associated with time lost from
work or usual activities and adding these to the direct
costs. Productivity loss was costed using the human ca-
pital approach (19), using age- and sex-adjusted average
wage rates as a value of patients’ time. Time lost from
usual daily activities was valued as leisure time according
to the recommendations of the U.K. Department of
Transport (43% of the value of paid employment) (20).
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calculated by dividing the di¡erence in the mean daily
costs between the two treatment groups by the
di¡erence in the mean rate of success (21), using the
following formula:
ICER
¼ mean cost of treatmentAmean cost of treatment B
mean effectiveness rate of treatmentAmean effectiveness rate of treatment B
Statistical analysis
Data from the intent-to-treat populations were used in
the statistical analyses, all of whichwere planned a priori.
Di¡erences between treatment groups were deter-
mined using pair-wise comparisons (Van Elteren exten-
sion to the Wilcoxon rank sum test and the Cochran
Mantel^Haenszel test, controlling for cluster of coun-
tries, age, sex and baseline), with the level of signi¢cance
taken as 5%.Ninety-¢veper centcon¢dence intervals for
the ICERs were calculated using the non-parametric
‘bootstrap’method technique (22).Bootstrap resamples
of the original cost/e¡ectpairs were generatedby taking
a random sample from each treatment groupwith repla-
cement from the original data, and the ICERs calculated
for allbootstrap resamples.The 95% con¢dence intervals
were calculated by ranking the bootstrap resamples
from the least cost^ e¡ective to themost cost^e¡ective
and excluding the top and bottom 2.5% of values.
Sensitivity analysis
Sensitivity analyses were used to test underlying
assumptions in the analysis. For the endpoint based365 patients re
peri
281 patients
139 received 
placebo
27 withdrew . Reasons for
withdrawal:
16 adverse event
1 treatment failure
2 non-compliance
2 failure to return
6 other
112
completed trial
FIG. 1. Flowchartof study.on improvement in FEV1, the criterion for success
was varied from Z5 to Z15%. For the proportions
of exacerbation-free patients, a best-case/worst-case
sensitivity analysis was undertaken. The best-case
analysis assumed that patients prematurely with-
drawn remained exacerbation-free for the remainder
of the study, whilst the worst case assumed that all
patients prematurely withdrawn experienced an exacer-
bation.
RESULTS
Of the 365 patients enrolled in the study, 281were ran-
domized to treatment:142 in the FP group and139 in the
placebo group (Fig.1).The groups were well matched for
baseline characteristics (Table1).
The clinical results have been published in detail pre-
viously (13). Compared with placebo, the FP group had
fewer exacerbations (111 vs. 76). Moreover, the number
whohadZ1moderate or severe exacerbationwas signif-
icantly higher in the placebo group (44/51 (86%) vs. 27/45
(60%);Po0.001). Patients in the FP group also had signi¢-
cantly (Po0.05) greater improvements in lung function
measurements such as peak expiratory £ow and FEV1.
Symptom scores for median daily cough and sputum vo-
lume were signi¢cantly (Po0.05) lower with FP. Both
treatments werewell tolerated.
Clinical e¡ectiveness
Improvement in FEV1
Compared with placebo, a signi¢cantly higher propor-
tion of patients in the FP group demonstrated a Z10%cruited to run-in 
od
 randomised
84 patients withdrew
142 received
fluticasone propionate
123
completed trial
19 withdrew . Reasons for  
withdrawal:
9 adverse event
4 treatment failure
6 other
TABLE 1. Baseline characteristics
Characteristics Placebo (n¼139) FP (n¼142)
Sex
Male 108 (78%) 99 (70%)
Female 21 (22%) 43 (30%)
Mean (range) age (years) 64 (50^75) 62 (49^75)
Smoking status
Smoker 68 (49%) 70 (49%)
Ex-smoker 70 (50%) 72 (51%)
Unknown 1 (1%) 0
History ofatopy*
Yes 9 (6%) 4 (3%)
Mean (SD) baseline FEV1 (l) 1.52 (0.62) 1.60 (0.58)
Mean (SD) FEV1/FVCratio (%) 55 (14) 60 (17)
Mean (SD) FEV1% predicted 55 (17) 59 (18)
Mean (SD) bronchodilator reversibility
FEV1 (%) 8 (7) 7 (7)
Predicted FEV1(%) 4.0 (3.9) 4.0 (4.0)
FEV1, forced expiratory volume in1s;FVC, forcedvital capacity.
*De¢nedbypatientquestionnaire.
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135 (19%);Po0.02).FEV1datawere not available for10 pa-
tients (6FFP; 4Fplacebo).
Exacerbation-free patients
The proportion of patients without an exacerbationwas
not signi¢cantly di¡erent between the groups (90/142
(63%) vs. 80/139 (58%); P¼0.32). The proportion of pa-
tients who were free of moderate/severe exacerbations
was signi¢cantly higher in the FP group (107/142 (75%) vs.
87/139 (63%); P¼0.02).
Use of health care resources
Patients in the placebo group hadmore out-patient con-
tacts with general practitioners (47 vs. 32) and hospitals
(47 vs. 24 outpatient visits and 3 vs. 0 emergency room
visits) than those in the FPgroup (Table 2); placebogroup
patients also spent more days as inpatients in hospital
(87 vs. 44).
Costs
Direct and indirect costs are summarized in Table 2.
Non-drug direct health-care costs were lower in the FP
group (d0.64 vs. d1.86/ patient/day). When medication
costs were considered, direct COPD costs were not sig-
ni¢cantly di¡erentbetween the groups (d2.75 vs. d2.72).
Including costs of lost productivity, total costs were low-
er in the FP group (d3.65 vs. d4.06), although this di¡er-ence was not signi¢cant, possibly because the clinical
trialwas powered on clinical rather than cost endpoints.
Cost^e¡ectiveness
Improvement in FEV1
From anNHSperspective, themean incremental cost to
improve a patient’s FEV1byZ10% over the 6 month per-
iod was d0.25/day (Table 3). This equates to a 6 month
incremental cost of d45.50 per patient. From a societal
perspective, the ICERwas negative (d3.39), indicating
that on average, improvements in lung function with FP
were achieved at a net cost saving relative to placebo.
Fromboth theNHS and societal perspective, the 95%
con¢dence intervals for improvement in FEV1 crossed
zero. Interpretation of negative cost^ e¡ectiveness ra-
tios is challenging as they may be due to an increased
bene¢t and a reducedcost (highlydesirable) or a reduced
bene¢t and an increased cost (highly undesirable).The si-
tuation ismade clear by plotting the results on the cost^
e¡ectiveness plane (Fig. 2), which shows the distribution
of ICERs from the bootstrap procedure. Figure 2 shows
that FP was consistentlymore e¡ective than placebo. By
excluding the top and bottom 2.5% of values to obtain
the limits of the 95% con¢dence interval, the lower limit
falls in thebottomright-handquadrantof theplane (FP is
bothmore e¡ective and cost-saving) and the upper limit
falls in the top right-hand quadrant (FP is more e¡ective
andmore costly).
Cost^ e¡ectiveness acceptability curves were con-
structed from these data to examine the cost^e¡ective-
ness of FP for varying levels of willingness to pay for
TABLE 3. ICERs in pounds sterling (1998) based on directcosts (NHSperspective) and direct plus indirectcosts (societal per-
spective)
Parameter ICER (95% bootstrap CLa)
NHS perspective
Costperday to achieve
PatientwithZ10% improvement in FEV1 0.25 (18.6,12.27)
Exacerbation-free patient 0.54 (87.08,12.09)
Moderate/severe exacerbation-free patient 0.25 (16.52,41.15)
Societal perspective
Costperday to achieve
ge;10% improvement in FEV1 3.39 (28.90,12.88)
Exacerbation-free patient* 7.19 (118.24,18.11)
Moderate/severe exacerbation-free patient 3.28 (26.67,45.23)
aNinety-¢ve percentcon¢dence limits calculatedusinga non-parametric bootstrap technique.
CI, con¢dence interval;FEV1, forced expiratory volume in1s; ICER, incremental cost^e¡ectiveness ratio.
TABLE 2. Summaryof resourcesused and direct and indirectcosts (dailycost per patient inpounds sterling (1998))
Placebo FP
Parameter Units Mean
cost (SD)
Median cost
(range)
Units Mean
cost (SD)
Median cost
(range)
Di¡erencea inmean
cost (95% CI)
Hospitalresource
A& Evisits 3 0.02 (0.12) 0.00 (0.00^1.18) 0 0.00 (0.00) 0.00 (0.00^0.00)
Inpatientdays 86 1.25 (7.07) 0.00 (0.00^57.39) 44 0.52 (4.32) 0.00 (0.00^49.06)
ICUdays 1 0.29 (3.42) 0.00 (0.00^40.36) 0 0.00 (0.00) 0.00 (0.00^0.00)
Outpatient visits 47 0.25 (0.67) 0.00 (0.00^4.35) 24 0.10 (0.30) 0.00 (0.00^2.01)
GPcontacts (surgery) 17 0.01 (0.03) 0.00 (0.00^0.31) 9 0.00 (0.01) 0.00 (0.00^0.10)
GPcontacts (home) 30 0.04 (0.18) 0.00 (0.00^1.93) 23 0.02 (0.07) 0.00 (0.00^0.45)
Directcosts excludingdrugs 1.86 (9.22) 0.00 (0.00^79.39) 0.64 (4.35) 0.00 (0.00^49.06)
Medication costs
Studydrug 0.00 1.23
Rescuemedication 0.02 0.02
COPD-related drugs 0.84 0.85
All directcosts 2.72 (9.22) 0.86 (0.86^80.25) 2.75 (4.35) 2.11 (2.11^51.16) 0.03
(1.72,1.54)
Days lost (indirectcosts)b 683 1.35 (3.87) 0.00 (0.00^25.81) 503 0.90 (3.39) 0.00 (0.00^26.31)
Total costs (direct plus indirect) 4.06 (11.75) 0.86 (0.86^86.45) 3.65 (6.24) 2.11 (2.11^59.06) 0.42
(2.7,1.62)
aCalculatedusing bootstrappingmethod.
bAbsence fromwork/usual activities.
Abbreviations: A & E, accident and emergency;GP, generalpractitioner; ICU¼intensive care unit.
216 RESPIRATORYMEDICINEimprovements in FEV1 (Fig. 3). From a societal perspec-
tive, FP was more e¡ective and less costly 68% of the
time (intercept with the y-axis). From an NHS perspec-
tive,FP is cost^ e¡ective formore than 80% of the time if
decision-makers arewilling topay an additionald5.00 per
day to improve FEV1byZ10%.Exacerbation-free patients
Although there were no signi¢cant di¡erences between
the treatment groups in terms of the proportion of pa-
tients remaining free of an exacerbation of any severity
at the end of treatment, signi¢cantly more patients in
FIG. 2. Plot of bootstrapped ICERs based onZ10% increase
in forced expiratory volume in1s for NHS and societal perspec-
tives.Pointsmarked are average ICERs for eachperspective.
FIG. 3. Cost^e¡ectiveness acceptability curves forZ10% im-
provementin forcedexpiratory volumein1s (FEV1) forNHSand
societalperspectives.
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FIG. 4. Cost^e¡ectiveness acceptability curves for avoidance
of amoderate or severe exacerbation for NHS and societal per-
spectives.
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tions at the end of the study. From an NHS perspective,
the incremental cost permoderate/severe exacerbation-
freepatientwasd0.25 perday, ord45.50 perpatientover
the 6-month period.The cost^ e¡ectiveness acceptabil-
ity curve (Fig. 4) shows that if decision-makers arewilling
to pay an additional d15 per patient per day, FP would be
more cost^ e¡ective in approximately 90% of cases.The
acceptability curve from a societal perspective is also
shown in Fig. 4.
Sensitivity analysis
The results were generally robust to changes in the un-
derlying assumptions.When the criterion for improve-
ment in FEV1 from baseline was varied from Z5 to
Z15%, the ICERs remained relatively constant; the addi-
tional direct cost per day ranged from d0.22 (Z5% im-
provement) to d0.31 (Z15% improvement).
The ICERs (NHSperspective) formoderate/severe ex-
acerbation-free patients were relatively constant for
both assumptions (cost per moderate/severe exacerba-
tion-free patient of d0.23^d0.25 per day).
DISCUSSION
One of thekey areas for futureresearch identi¢edby the
recently published Global Initiative for Chronic Obstructive
218 RESPIRATORYMEDICINELung Disease (GOLD) guidelines (23), was better infor-
mation on the cost and resource use of treatments used
in COPD.This is the ¢rst prospective economic evalua-
tion to assess the cost^ e¡ectiveness of inhaled corticos-
teroids in patients with clearly de¢ned, non-asthmatic
COPD.
This study demonstrates that treatment of patients
with moderate-to-severe COPD with FP produced sig-
ni¢cant improvements in a range of clinical outcomes, in-
cluding increased FEV1and a reduction in the number of
moderate-to-severe exacerbations. Importantly, treat-
ment with FP did not result in signi¢cant changes in
COPDmanagement costs from either an NHS or a soci-
etal perspective.This treatmentcan thereforebe consid-
ered cost^ e¡ective in this patient population.This range
of improvements is important both from the patient’s
viewpoint and economically, as COPD represents a sig-
ni¢cantburden on health-care resources (24). Reduction
in the frequency and severity of exacerbations is particu-
larly important due to the high costs of managing these
events (24). In addition, 40% of patients who have a
COPD exacerbation with respiratory failure will die
within a year, and only 26% of those who survive report
good quality of life following such an event (25).
Although the addition of FP increased drug costs, this
was o¡set by reductions in non-drug health-care costs.
This result illustrates that better control of the disease
mayreduce some of the clinical and economic burden as-
sociated with COPD, and consideration of drug acquisi-
tion costs alone will underestimate the economic value
of treatment. From a societal perspective, FP resulted
in lower mean costs, although this was not statistically
signi¢cant.Whilst societal costs are an important con-
sideration in economic evaluation, they are less impor-
tant to health-care purchasers as potential productivity
savings would not be realized within their budget. For
this reason, an NHS perspective was of primary consid-
eration in this study.
In this study, the ICERs suggest that adding FP to the
treatment of COPD patients tended to result in a small
increase in expenditure from an NHS perspective and a
net decrease from a societal perspective. One earlier
economic analysis of inhaled corticosteroids in a mixed
asthma and COPD (about 20%) population inThe Neth-
erlands similarly found that improvements in lung func-
tion were achieved at a low incremental cost (26); the
ICER for the corticosteroid group vs. the placebo group
was US$200 (approximately d135) per 10% increase in
FEV1. Results in this study suggest a comparable level of
cost^ e¡ectiveness,with a 6month costper10%FEV1 im-
provement of d45.50. However, this study was con-
ducted in a considerably more severe population, and it
is likely that bene¢ts in this population will be more
highly valued by patients and physicians than those
achieved in a mild COPD population with fewer symp-
toms and infrequent exacerbations. In designing ourstudy, we took steps to ensure that we enrolled only pa-
tients with largely irreversible chronic air£ow obstruc-
tion, by setting inclusion criteria of a lowered FEV1 (35^
90%), an FEV1/FVC ratio of r70% and reversibility of
o15% to salbutamol 400 or 800mg, and requiring that
patients be either current or exsmokers with a history
of chronic bronchitis. Investigating physicians also made
sure that the patients’ histories were in keeping with
the description of COPD in the European Respiratory So-
ciety Consensus Statement (16) and that those with a his-
tory of asthmawere excluded.
There are a number of limitations that need to be con-
sidered. Although the trialwas 6months in duration, it is
unclear whether these results can be extrapolated be-
yond this time period. However, evidence from longer-
term inhaled corticosteroid trials such as the inhaled
steroids in obstructive lung disease (ISOLDE) study, also
conducted in patients with moderate-to-severe COPD,
suggests that the bene¢t in exacerbation reduction is
maintained over 3 years, and that a signi¢cant reduction
in therate of decline of health status can alsobe achieved
(12).These ¢ndings suggest that the clinical bene¢ts of in-
haled corticosteroids can be maintained, although the
economic consequences remain to be fully determined.
In addition, the cost^ e¡ectiveness of inhaled corticos-
teroids has not been determined in patients with milder
disease, although as these patients have fewer exacerba-
tions, cost^ e¡ectivenessmay provemore di⁄cult to de-
monstrate.
Another potential problem in interpreting this analy-
sis is the lack of published studies of the cost^e¡ective-
ness of other potential interventions in COPD. As
recommendedby theGOLDguidelines (23), further eva-
luation of the cost^ e¡ectiveness of treatment options in
this disease is of substantial importance. In this study, a
generic measure of health outcome, such as the quality
adjusted life year, would have enabled us to evaluate FP
treatment in thewider contextof other chronic diseases,
but health status was not directly measured. However,
the clinical bene¢ts in terms of exacerbations and symp-
toms observed are clearly important indirect indicators
of the bene¢cial e¡ect of FP on health status in COPD
(27). One ¢nal limitation that is common to the over-
whelming majority of economic analyses conducted
within clinical trials, is that this study was not primarily
powered to detect cost di¡erences between the treat-
mentgroups. In this instance, it is importantwhen inter-
preting the data to examine the con¢dence intervals
around the ICER, the distribution of bootstrap resam-
ples on the cost^ e¡ectiveness plane and the acceptabil-
ity curve. As indicated by Briggs (28), the lack of power
in these studieswillbe demonstratedby wide con¢dence
intervals around the ICER.
Another study of the cost^ e¡ectiveness of FP has re-
cently been reported (29) in which 74 patients with ob-
structive airways disease (asthma and COPD) were
COST-EFFECTIVENESSOFFLUTICASONEPROPIONATE INCOPD 219treated for 1 year with either FP 250mg or placebo
(the DIMCA programme). This study is not strictly
comparablewith ours, given thatwe studied only COPD
patients, whose disease was at a more advanced stage,
andwho received a larger dosage of FP. It is nevertheless
interesting that the authors reported the incremental
cost of one additional patient achieving a clinically
relevant di¡erence in dyspnoea to be US$1674. They
concluded that early intervention with FP resulted in
signi¢cant health gains in lung function, dyspnoea
and quality of life at relatively low ¢nancial cost
(29).These ¢ndings support the results of our investiga-
tion of more severely ill patients with well-de¢ned
COPD.
In this 6 month, prospective, randomized, placebo-
controlled clinical trial, the treatment of patients with
moderate-to-severe COPD with FP provided signi¢cant
clinical bene¢ts, small and non-signi¢cant increases in di-
rect health-care costs, and a reduction in total costs.
These clinical and economic bene¢ts, in a disease that is
relentlessly progressive, very disruptive to patients’ lives
and for which treatment options are limited, suggest
that there is both a clinical and an economic rationale
for the use of inhaled corticosteroids over a period of
at least 6 months in the treatment of symptomatic
COPD.
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